Workflow
Supernus Pharmaceuticals(SUPN) - 2025 Q2 - Quarterly Results

General Information This section provides administrative details of the Form 8-K filing, including registrant identity and registered securities Filing Details This section outlines the administrative specifics of the Form 8-K filing, including the registrant's identity, the filing date, and the securities registered - Registrant: Supernus Pharmaceuticals, Inc.2 - Date of Report (earliest event reported): July 22, 20252 Registered Securities | Title of each class | Trading Symbol | Name of each exchange on which registered | | :------------------ | :------------- | :---------------------------------------- | | Common Stock, $0.001 par value per share | SUPN | The Nasdaq Stock Market LLC | Item 2.02 Results of Operations and Financial Condition This section details the company's announcement regarding its second quarter 2025 financial results and related events Second Quarter 2025 Earnings Announcement Supernus Pharmaceuticals, Inc. announced the schedule for its second quarter 2025 earnings release and the subsequent conference call and webcast - Expected Q2 2025 Earnings Release Date: After market closes on Tuesday, August 5, 20254 - Conference Call and Webcast: Tuesday, August 5, 2025, at 4:30 p.m. E.T.4 - A press release detailing this announcement was issued on July 22, 2025, and is furnished as Exhibit 99.14 Item 9.01 Financial Statements and Exhibits This section lists all financial statements and exhibits included as part of the Form 8-K filing Exhibits Filed This section lists the exhibits accompanying the Form 8-K filing, specifically the press release and the Inline XBRL cover page List of Exhibits | Exhibit | Description | | :------ | :---------- | | 99.1 | Press Release dated July 22, 2025 filed as an Exhibit pursuant to Item 2.02 hereof | | 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | Signatures This section provides the official authorization and signing details for the Form 8-K report Report Authorization This section confirms the official signing and authorization of the Form 8-K report by a duly authorized officer of the registrant - The report was signed on July 22, 2025, by Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus Pharmaceuticals, Inc.10